Little Rock, ARNCT04803201Now EnrollingIRB Ready

Angioimmunoblastic T-cell Lymphoma Clinical Trial in Little Rock, AR

Access cutting-edge angioimmunoblastic t-cell lymphoma treatment through this phase 2 clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.

Sponsored by Alliance for Clinical Trials in Oncology

Quick Self-Assessment

See if you qualify for this Little Rock location

Preparing your pre-screening questions…

Expert Care in Little Rock

Access angioimmunoblastic t-cell lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related angioimmunoblastic t-cell lymphoma treatment provided free

Apply for This Little Rock Location

Check if you qualify for this angioimmunoblastic t-cell lymphoma clinical trial in Little Rock, AR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Little Rock

    Convenient for AR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Little Rock site if eligible
  4. 4Begin participation

About This Angioimmunoblastic T-cell Lymphoma Study in Little Rock

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.

Sponsor: Alliance for Clinical Trials in Oncology

Who Can Participate

Inclusion Criteria

Histologically confirmed diagnosis of peripheral T-cell lymphoma (PTCL) with \< 10% CD30 expression by immunohistochemistry in the following subtypes (by local review): nodal T-cell lymphoma with T-follicular helper (TFH) phenotype (TFH-PTCL), follicular T-cell lymphoma, PTCL-not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), enteropathy associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma
Patients with expression of CD30 in \>= 10% of the tumor (based on local immunohistochemistry review) regardless of histology will not be permitted
Patients with a diagnosis of other PTCL subtype histologies other than those specified in the inclusion criteria are excluded including large cell transformation of mycosis fungoides
Patients will be stratified by presence or absence of TFH phenotype (i.e. diagnosis of AITL, TFH-PTCL, follicular T-cell lymphoma) based on local review of pathology. Determination of TFH phenotype can be defined by expression of two or more of the following markers CD10, BCL6, CXCL13, ICOS, and PD1 by immunohistochemistry
Measurable disease as defined by the Lugano criteria
No prior systemic therapy for lymphoma (excluding corticosteroids)
Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =\< 7 days prior to registration is required
Age \>= 18 years
Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
Platelet count \>= 75,000/mm\^3 (\>= 50,000/mm\^3 if secondary to bone marrow involvement from lymphoma per investigator assessment; the first 12 patients on each arm of the study must have platelets \>= 75,000/mm\^3 regardless of bone marrow involvement)
Absolute neutrophil count (ANC) \>= 1,000/mm\^3
Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =\< 3.0 x upper limit of normal (ULN) \
Except in subjects with documented liver involvement by lymphoma
Calculated creatinine clearance \>= 30 mL/min by Cockcroft-Gault formula
Total bilirubin =\< 2.0 x ULN \
Except in cases of Gilbert's Syndrome or documented liver or pancreatic involvement by lymphoma
Archival tissue must be available for submission
Patients known to have HTLV 1/2 are excluded
Patients with known central nervous system involvement are excluded
No active viral infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. Those who are seropositive (e.g. hepatitis B core antibody \[Ab\] positive) are permitted if they are negative by polymerase chain reaction (PCR). Those who are seropositive for hepatitis B and are negative for hepatitis B virus (HBV) deoxyribonucleic acid (DNA) by PCR must receive concomitant hepatitis B directed antiviral therapy. Those who have hepatitis C Ab positivity who have completed curative therapy for hepatitis C with negative hepatitis C PCR are eligible
Patients with history of HIV are eligible if they have an undetectable viral load for at least 6 months
No active uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment). Patients with Epstein-Barr virus (EBV) viremia related to their lymphoma are permitted
No concurrent malignancy requiring active therapy within the last 3 years with the exception of basal cell carcinoma limited to the skin, squamous cell carcinoma limited to the skin, carcinoma in situ of the cervix, breast or localized prostate cancer. Adjuvant hormonal therapy for cancer previously treated for curative intent is permitted
Patients must have documented left ventricular ejection fraction of \>= 45%
No significant active cardiac disease within the previous 6 months including:
New York Heart Association (NYHA) class III or IV congestive heart failure
Unstable angina or angina requiring surgical or medical intervention; and/or
Myocardial infarction
No contraindication to any drug in the chemotherapy regimen, including neuropathy \>= grade 2
Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study. Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Little Rock?

Yes, this clinical trial (NCT04803201) has an active research site in Little Rock, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Angioimmunoblastic T-cell Lymphoma Treatment Options in Little Rock, AR

If you're searching for angioimmunoblastic t-cell lymphoma treatment options in Little Rock, AR, this clinical trial (NCT04803201) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Little Rock research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced angioimmunoblastic t-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all angioimmunoblastic t-cell lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Little Rock, AR

See all lymphoma clinical trials recruiting in Little Rock — not just this study.

Browse Lymphoma Trials in Little Rock →

Browse More Trials by Condition

Lymphoma TrialsMultiple Myeloma TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsPeripheral T-Cell Lymphoma TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Little Rock?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Little Rock, AR